/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Gastroesophageal Cancers | David H Ilson, MD, PhD
Gastroesophageal Cancers | David H Ilson, MD, PhD

Gastroesophageal Cancers | David H Ilson, MD, PhD

Research To Practice | Oncology Videos · Aug 19, 2026

GI cancer updates: Checkpoint inhibitors are a game-changer for MSI-high tumors, and new drug combos are improving survival across the board.

Keynote 585 Trial Failure Linked to Chemo Backbone, Not Immunotherapy

While the Keynote 585 trial (doublet chemo + pembrolizumab) failed overall, its small FLOT chemotherapy subgroup mirrored the positive results of the Matterhorn trial (FLOT + durvalumab). This suggests the choice of a less aggressive chemotherapy backbone, not the immunotherapy concept, was the critical factor in the trial's negative outcome.

Gastroesophageal Cancers | David H Ilson, MD, PhD thumbnail

Gastroesophageal Cancers | David H Ilson, MD, PhD

Research To Practice | Oncology Videos·3 months ago

First-Line Immunotherapy Triples 5-Year Survival in Metastatic Esophageal Cancer

Long-term follow-up from multiple major trials (Checkmate 649, Keynote 590) consistently demonstrates that adding a checkpoint inhibitor to first-line chemotherapy produces durable benefits. This combination more than doubles or triples the 5-year overall survival rate from ~3-5% with chemotherapy alone to over 11-13% with immunotherapy.

Gastroesophageal Cancers | David H Ilson, MD, PhD thumbnail

Gastroesophageal Cancers | David H Ilson, MD, PhD

Research To Practice | Oncology Videos·3 months ago

Adjuvant Durvalumab Boosts Survival Even with Incomplete Treatment

In the Matterhorn trial, while completing the full perioperative FLOT plus durvalumab regimen yields the best outcomes, the immunotherapy's benefit persists even with partial adherence. Patients receiving some or even no adjuvant durvalumab still showed superior event-free survival compared to chemotherapy alone, a key finding for real-world practice.

Gastroesophageal Cancers | David H Ilson, MD, PhD thumbnail

Gastroesophageal Cancers | David H Ilson, MD, PhD

Research To Practice | Oncology Videos·3 months ago

Dual Immunotherapy Fails to Improve on Single-Agent Standard in Metastatic Disease

The ATTRACTION-6 trial surprisingly found that adding combination immunotherapy (ipilimumab + nivolumab) to first-line chemotherapy did not improve overall survival over chemotherapy alone in metastatic gastric cancer. This negative result reinforces that adding a single-agent checkpoint inhibitor to chemotherapy remains the global standard of care.

Gastroesophageal Cancers | David H Ilson, MD, PhD thumbnail

Gastroesophageal Cancers | David H Ilson, MD, PhD

Research To Practice | Oncology Videos·3 months ago

Immunotherapy Replaces Chemo for Locally Advanced MSI-High Gastric Cancers

Two phase 2 trials (NEONAPIGA, INFINITY) show that preoperative combination immunotherapy achieves pathologic complete response rates of nearly 60% in MSI-high gastric cancers. This success establishes a new paradigm, potentially allowing non-operative management and avoidance of surgery for patients who respond well.

Gastroesophageal Cancers | David H Ilson, MD, PhD thumbnail

Gastroesophageal Cancers | David H Ilson, MD, PhD

Research To Practice | Oncology Videos·3 months ago